Recent Research Funding

Our faculty secure major research grants from various National Institutes of Health as well as private sources.

  • MARCH proteins, members of a host protein family that targets HIV. Spyridon Stavrou (Principal Investigator). NIH/NIAID. $1,974,920. 12/1/2021-11/1/2026.
  • Ribosome Heterogeneity in C. neoformans. John Panepinto (Principal Investigator). NIAID / NIH. 8/1/2021-7/1/2026.
  • The role of neutrophils in the age-driven decline in anti-pneumococcal vaccine responses. Elsa Bou Ghanem (Principal Investigator). NIA-R01. $1,575,931. 9/1/2021-5/1/2026.
  • The role of neutrophils in the age-driven decline in anti-pneumococcal vaccine responses. Elizabeth Wohlfert (Co-Investigator). NIH. $2,634,726. 9/1/2021-3/1/2026.
  • Bacterial sialometabolic activity impacts periodontal immunity and microbiota. Yijun Sun (Co-Investigator). NIH. $1,930,340. 9/1/2020-8/1/2025.
  • Advanced computational approaches to delineating dynamic cancer progression processes by using massive static sample data. Yijun Sun (Principal Investigator). NIH. $1,964,300. 4/1/2020-3/1/2025.
  • The Organization and Function of the Toxoplasma Daughter Cell Scaffold. Ira Blader (Co-Principal Investigator). NIH. 1/1/2020-12/1/2024.
  • Conserved Proteus mirabilis genetic requirements for colonization of the catheterized urinary tract. Chelsie Armbruster (Principal Investigator). National Institute of Diabetes and Digestive and Kidney Diseases. 9/1/2019-5/1/2024.
  • Function and regulation of the essential RNA binding protein, DRBD18. Laurie Read (Principal Investigator). NIH. $2,121,078. 6/1/2019-5/1/2024.
  • The Translational Response of C. neoformans to Oxidative Stress and Macrophage Phagocytosis. Elizabeth Wohlfert (Co-Investigator). NIH. $447,863. 7/1/2021-6/1/2023.
  • The Translational Response of C. neoformans to Oxidative Stress and Macrophage Phagocytosis. John Panepinto (Co-Principal Investigator). NIAID / NIH. 7/1/2021-6/1/2023.
  • Slowing of the polyomavirus DNA replication fork in response to DDR. Thomas Melendy (Principal Investigator). NIH - NIAID. $438,625. 5/1/2021-4/1/2023.
  • The role of the extracellular adenosine pathway and neutrophils during infective endocarditis induced by S. pneumoniae. Elsa Bou Ghanem (Contributor). American Heart Association-Postdoctoral Fellowship to Manmeet Bhalla. $136,750. 4/1/2021-3/1/2023.
  • Features of PMN senescence that lead to susceptibility to pneumococcal infection. Elsa Bou Ghanem (Co-Investigator). NIA-R21. $469,115. 3/1/2021-2/1/2023.
  • Antimicrobial photodynamic therapy (aPDT) for eradication of microbial biofilms on urinary catheters. Chelsie Armbruster (Principal Investigator). CTSI Pilot Grant via the National Center for Advancing Translational Sciences. $45,530. 1/1/2022-12/1/2022.
  • Antimicrobial photodynamic therapy (aPDT) for eradication of microbial biofilms on urinary catheters. Anthony Campagnari (Co-Principal Investigator). NIH National Center for Advancing Translational Sciences (NCATS) Pilot Studies Program. $45,530. 1/1/2022-12/1/2022.
  • Electrical Stimulation for Infection Control of the Skin-Implant Interface of Osseointegrated Prostheses. Anthony Campagnari (Co-Investigator). Congressionally Directed Medical Research Program: Peer Reviewed Orthopedic Research Program. $749,188. 10/1/2020-10/1/2022.
  • SBIR: Testing Efficiency, Pharmacodynamic and Pharmacokinetic of New Immunotherapeutic Drug for Ovarian and Melanoma Cancer. Thomas Melendy (Co-Principal Investigator). NIH - NCI. 7/1/2021-9/1/2022.
  • UB Center for Advanced Technology in Big Data and Health Sciences. Thomas Melendy (Co-Investigator). NYS Center of Excellence in Bioinformatics and Life Sciences. 7/1/2021-9/1/2022.
  • Electrical Stimulation for Infection Control of the Skin-Implant Interface of Osseointegrated Prostheses. Anthony Campagnari (Co-Investigator). Peer Reviewed Orthopedic Research Program of the Congressionally Directed Medical Research Program. $7,490,000. 9/1/2020-8/1/2022.